RCS - Cambridge Cognition - CANTAB® used for major global brain health study

Cambridge Cognition HoldingsAnnouncement

06/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250306:nRSF5484Za&default-theme=true

RNS Number : 5484Z  Cambridge Cognition Holdings PLC  06 March 2025

6(th) March 2025

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

CANTAB® demonstrates substantial value in one of the largest brain health
studies ever conducted

Cambridge Cognition (AIM: COG), the brain health software group specialising
in digital products to advance clinical research and patient treatment,
announces its involvement in one of the world's largest brain health studies,
the Intuition Brain Health study(1), demonstrating the significant value of
its proprietary digital cognitive assessments.

On 4(th) March 2025, leading scientific journal Nature Medicine(2) published
results from the Intuition Brain Health study, sponsored by Biogen, Inc., in
collaboration with Apple, Inc. The study enrolled a representative sample of
23,004 participants across the United States and relied on Cambridge
Cognition's CANTAB platform for the core cognitive assessment.

Cambridge Cognition was selected as a partner for the study for its proven
ability to deliver reliable digital cognitive measurements in remote settings,
highlighting the platform's unique capabilities for large-scale, unsupervised
cognitive evaluation. The study demonstrates the feasibility of large-scale,
cognitive assessments using smartphones alongside smartwatch technology and
the significant potential to make brain health monitoring widely accessible
for the general population. This validates the sensitivity of Cambridge
Cognition's technology for the measurement of brain health across the
lifespan.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"The Intuition study powerfully validates CANTAB's accuracy at scale and
reinforces our leadership in digital brain health. As healthcare systems
increasingly turn to digital solutions to address urgent challenges, this
represents a significant opportunity which we are well positioned to meet."

 

This study highlights a strategically significant market opportunity for
Cambridge Cognition's cognitive assessment platform, and we will be continuing
to thoroughly evaluate the commercial potential for real-world brain health
monitoring applications using our industry-leading software solutions in the
coming months.

 

Key highlights of the study:

 ●    Scalability & Accessibility: Emphasises CANTAB
      (https://www.googleadservices.com/pagead/aclk?sa=L&ai=DChcSEwirhvP79vKLAxVumVAGHYGvJ0UYABAEGgJkZw&co=1&gclid=CjwKCAiAiaC-BhBEEiwAjY99qJsdmuANlGRJoaQO5QDR_6_EE-1BPsAQPZv8nmXpnMdtSISl3mXm3RoC2-sQAvD_BwE&ohost=www.google.com&cid=CAESVeD2eki6COws7WhOfOez6enttPncqrT_jphtH6_YHhs7eXxudGYZd1tE8YqISi_srKPKRp9BVNC-OK8oLuMVjscpaDe70nNlOW_3xgvlssrT8_MRrbs&sig=AOD64_1FXMkxkt9pQc7e0bW2cePxmbHF7w&adurl=&q=)
      's proven ability to scale across diverse populations with high adherence
      across an extended period, making brain health monitoring widely accessible.
 ●    Sensitivity to mild cognitive impairment (MCI): Highlights the impressive
      performance metrics in detecting mild cognitive impairment to reinforce
      Cambridge Cognition's leadership in cognitive assessment.
 ●    Validation & Future Leadership: The Intuition study provides evidence of
      Cambridge Cognition's status as the preferred partner and leading innovator in
      changing the landscape of brain health assessments.

1.
https://clinicaltrials.gov/study/NCT05058950 (https://clinicaltrials.gov/study/NCT05058950)

2.
https://www.nature.com/articles/s41591-024-03475-9#Sec16 (https://www.nature.com/articles/s41591-024-03475-9#Sec16)

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths                 cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products that advance brain health research and treatment.

The company offers four core products: CANTAB¨ assessments-providing
scientifically validated, highly sensitive, precise, and objective measures of
cognitive function correlated to neural networks; a flexible and proven eCOA
platform with an extensive library of instruments, enabling efficient study
setup and scalable data capture; rater training services that standardise
assessment delivery and scoring across clinical trials and quality assurance
tools that ensure data integrity by automatically detecting deviations in
administration and scoring, saving time and money. These products collectively
improve clinical trial outcomes, enable early patient identification, and
enhance global efficiency in healthcare and pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.cambridgecognition.com%2F&data=05%7C02%7Chgriffiths%40hudsonsandler.com%7Cc696c6a3150d40f91a9508dcfdd13b58%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638664322305026349%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=vQVOIVxNQ8WYYOufDnSVKUH0oa7PLvXjnP0VT%2FzCfJc%3D&reserved=0)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGGFMKRGKZZ